0001179110-14-008883.txt : 20140521 0001179110-14-008883.hdr.sgml : 20140521 20140521185129 ACCESSION NUMBER: 0001179110-14-008883 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140519 FILED AS OF DATE: 20140521 DATE AS OF CHANGE: 20140521 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quisel John D CENTRAL INDEX KEY: 0001586788 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 14861873 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2014-05-19 0 0001280600 ACCELERON PHARMA INC XLRN 0001586788 Quisel John D 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 VP General Counsel & Secretary Common Stock 2014-05-19 4 M 0 2000 0.92 A 2000 D Common Stock 2014-05-19 4 S 0 2000 31.49 D 0 D Common Stock 2014-05-19 4 M 0 7000 3.88 A 7000 D Common Stock 2014-05-19 4 S 0 6100 31.29 D 900 D Common Stock 2014-05-19 4 S 0 900 32.20 D 0 D Option to Purchase Common Stock 0.92 2014-05-19 4 M 0 2000 0 D 2016-11-15 Common Stock 25500 23500 D Option to Purchase Common Stock 3.88 2014-05-19 4 M 0 7000 0 D 2020-12-02 Common Stock 62500 55500 D The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2013. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.17 to $31.89, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by teh reporting person on March 5, 2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.86, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter. The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. /s/ Kevin F. McLaughlin, as attorney-in-fact for John D. Quisel 2014-05-21